3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Sarcopenia
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid
1
Heart Failure
1
Cardiotoxicity
1
Breast Neoplasms
1
Anemia, Aplastic
1
Interventions
Echocardiography
4
Electrocardiography
2
sulforaphane
1
schizandrin
1
sacubitril and valsartan sodium hydrate drug combination
1
pegfilgrastim
1
nicotinamide-beta-riboside
1
fructus schizandrae, radix ginseng, radix ophiopogonis drug combination
1
empagliflozin
1
Watchful Waiting
1
Vincristine
1
Tablets
1
Rituximab
1
Proton Therapy
1
Proteins
1
Prednisolone
1
Observation
1
Medical History Taking
1
Lenalidomide
1
Laser-Doppler Flowmetry
1
Exercise
1
Environmental Biomarkers
1
Echocardiography, Stress
1
Doxorubicin
1
Dexrazoxane
1
Cyclophosphamide
1
Clinical Laboratory Techniques
1
Chemoradiotherapy
1
Carvedilol
1
Blood Pressure Determination
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Cardiotoxicity
×
nicotinamide-beta-riboside
×
Clear all
NCT05732051
2023-03-17
NARNIA
University Hospital, Akershus
Phase 2
Recruiting
60 enrolled